pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,537 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6100Rare Disease1467Cardiology1094Hematology1031Immunology1015Vaccines919Pulmonology
  • Amgen seeks FDA hearing to keep rare kidney drug Tavneos amid safety concerns
    Amgen has asked the U.S. Food and Drug Administration for a hearing to argue against a proposed withdrawal of its rare‑disease drug Tavneos. The company submitted a data package containing real‑wo…
    BioSpace · 28d agoRegulatoryNegative↗ source
  • Merck grants royalty-free licenses for experimental HIV prevention pill to generic makers in 129 low-income countries
    Merck announced voluntary licensing agreements that let generic manufacturers produce its experimental HIV prevention pill, known as alimatravir, in low- and middle-income markets. The deals cover…
    STAT · 29d agoDealPositive↗ source
← prev
page 22 of 62
next →
73
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS724
Ophthalmology424
Pain406
Endocrinology & Metabolism389
Infectious Disease361
  • FDA panel backs compounding of epitalon, rejects emideltide in narrow vote
    The FDA advisory committee voted to allow compounding pharmacies to produce the peptide epitalon, while narrowly voting against allowing the production of emideltide. The decision follows the pane…
    STAT · 28d agoRegulatoryNeutral↗ source
  • Fatal gene-editing trial in China sparks ethics and oversight concerns
    A six-year-old girl in China died after receiving an experimental brain-directed CRISPR therapy, according to a report in Science. The tragedy has intensified calls for stronger ethical review and…
    STAT · 29d agoRegulatoryNegative↗ source
  • FDA panel backs compounding pharmacies to produce four peptide drugs, amid insulin pen shortage and Merck HIV pill license
    An FDA advisory committee voted to allow compounding pharmacies to prepare four peptide-based medicines, a decision hailed by supporters of peptide therapeutics. The briefing also mentioned that M…
    STAT · 29d agoRegulatoryPositive↗ source
  • Summit Therapeutics faces under a year of cash runway as FDA decision on ivonescimab looms
    Summit Therapeutics reported that its cash and short-term investments total just over $690 million, which the company says is insufficient to fund operations for a full year. The biotech’s lead ca…
    BioSpace · 29d agoRegulatoryNeutral↗ source
  • Roche drops Carmot’s acmopatide after Phase 2 success, shifts focus to enicepatide for weight loss and diabetes
    Roche announced it will stop developing acmopatide, an investigational obesity treatment acquired from Carmot Therapeutics. Acmopatide had met its primary endpoint in a Phase 2 trial in type 1 dia…
    BioSpace · 29d agoNeutral↗ source
  • U.S. drug shortages stem from weak regulation, not China competition, says expert
    In 2025 the United States faced 216 active drug shortages, limiting access to lifesaving medicines for patients. While the White House and national‑security officials have framed the problem as a…
    STAT · 29d agoRegulatoryNegative↗ source
  • White House science blueprint pushes billions toward AI firms, away from university life-science research
    The White House Office of Science and Technology Policy released a report titled “Science: A New Golden Age.” The document outlines a new direction for U.S. federal science funding. The plan calls…
    STAT · 29d agoRegulatoryNegative↗ source
  • Baxter recalls cefazolin injection after cardboard particles detected
    Baxter International announced a voluntary nationwide recall of lot LD175708 of its cefazolin in dextrose injection, a single‑dose 100 ml infusion bag. The recall was prompted by a report that car…
    fda recalls · 29d agoCRLNegative↗ source
  • Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
    Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
    BioSpace · 29d agoDealNeutral↗ source
  • Senate moves forward bill to require warning labels on ultra-processed foods and ban child-targeted junk-food ads
    The Senate Health, Education, Labor and Pensions Committee voted to advance a bill that would require the FDA to place prominent warning labels on ultra-processed foods high in sugar, salt or satur…
    STAT · 29d agoRegulatoryNeutral↗ source
  • Baxter voluntarily recalls Cefazolin in Dextrose injection after cardboard particles found
    Baxter International announced a voluntary nationwide recall of Lot LD175708 of its Cefazolin in Dextrose Injection, a single-dose infusion bag. The recall follows a report that cardboard particle…
    fda recalls · 29d agoCRLNegative↗ source
  • FDA advisory panel backs compounding pharmacies to produce four popular peptides, defying prior committee advice
    The Food and Drug Administration’s advisory panel voted to allow compounding pharmacies to manufacture four peptide drugs that have gained popularity among health‑seeking individuals. The recommend…
    STAT · 29d agoRegulatoryPositive↗ source
  • U.S. measles cases in 2026 already exceed total from record-breaking 2025 year
    The CDC reports 2,318 measles cases in the United States so far in 2026, surpassing the 2,289 cases recorded for the entire year of 2025. The increase makes 2026 the worst measles year since 1991,…
    STAT · 28d agoNeutral↗ source
  • Rigel Pharmaceuticals appoints Alison Hannah as executive vice president and chief medical officer
    Rigel Pharmaceuticals announced that it has hired Alison Hannah to serve as executive vice president and chief medical officer. Hannah joins Rigel after holding the same senior medical leadership…
    STAT · 28d agoPositive↗ source
  • Lidl US recalls Eridanous shortbread cookies over undeclared wheat, soy, milk, and egg allergens
    Lidl US announced a recall of its Eridanous Shortbread Cookies with Chocolate Truffle Coating & Apricot Filling, 11.6 oz boxes, after discovering that the packaging was in a foreign language and om…
    fda recalls · 29d agoRegulatoryNegative↗ source
  • Federal loan changes threaten future middle-class medical students
    The author, Gauri Gurumurthy, a third-year medical student, explains that she could attend medical school thanks to the federal Graduate PLUS loan program. On July 1, new provisions in the One Big…
    STAT · 29d agoNegative↗ source
  • Former FDA food safety chief warns nutrition push may overlook cyclospora outbreak risks
    Susan Mayne, who led the FDA’s Center for Food Safety and Applied Nutrition from 2015 to 2023, argues that nutrition and food safety cannot be treated separately. She says the two are linked and bo…
    STAT · 28d agoNeutral↗ source
  • Vaisala senior manager Girish Agarwal receives 1,000 incentive shares
    Vaisala Corporation disclosed that its senior manager Girish Agarwal was granted a share-based incentive. The transaction, reported on July 23, 2026, involved the receipt of 1,000 series A shares…
    globenewswire health · 29d agoNeutral↗ source
  • Vaisala Oyj discloses executive Girish Agarwal receiving 1,000 shares at no cost
    Vaisala Oyj, a Finnish climate‑measurement technology company listed on Nasdaq Helsinki, filed a regulatory notice on 23 July 2026 regarding an insider transaction. The notice identifies Girish Ag…
    globenewswire health · 29d agoRegulatoryNeutral↗ source
  • DSV A/S reports manager share transactions in latest company announcement
    DSV A/S issued Company Announcement No. 1171, informing the market of recent share transactions carried out by a company manager. The disclosure is made under Article 19 of EU Regulation 596/2014,…
    globenewswire health · 29d agoRegulatoryNeutral↗ source
  • Eli Lilly to seek FDA approval for retatrutide in early 2027 after Phase 3 trials show over 20% weight loss
    Eli Lilly said its next‑generation obesity drug retatrutide produced substantial weight loss in two late‑stage Phase 3 studies. The data were presented from the TRIUMPH‑2 and TRIUMPH‑3 trials, whic…
    BioSpace · 1mo agoPositive readoutPositive↗ source
  • GSK receives FDA approval for ROS1 inhibitor Jideytro, marking its first lung cancer drug
    GSK's FDA approval of Jideytro, a ROS1 inhibitor for advanced non-small cell lung cancer patients with ROS1 gene fusions who have already received ROS1-directed therapy, was announced on Wednesday.…
    BioSpace · 1mo agoApprovalPositive↗ source
  • Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trial
    Eli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…
    STAT · 1mo agoNegative readoutNeutral↗ source